Literature DB >> 16681241

Successful treatment of mucous membrane pemphigoid with tacrolimus.

Lakshmanan Suresh1, Luis Edmundo Martinez Calixto, Lida Radfar.   

Abstract

Mucous membrane pemphigoid (MMP) is a heterogeneous group of autoimmune, chronic inflammatory ubepithelial vesiculobullous disorders, predominantly affects the mucous membranes of the oral cavity and eyes of the elderly population. Oral manifestations of pemphigoid include desquamative gingivitis, ulcers, erythematous patches, erosions, vesicles and bullae located on the attached gingiva, palate, buccal mucosa, labial mucosa, and tongue. Diagnosis is based on history, clinical features and a biopsy stained with hematoxylin and eosin (H&E), and also direct and indirect immunofluorescence. Topical and systemic corticosteroids are the most commonly used medications for managing pemphigoid. Recently, topical tacrolimus has been successfully used in the treatment of ocular and skin pemphigoid. In this report we present a patient with longterm recalcitrant MMP that did not respond to conventional treatment but as treated successfully with tacrolimus ointment.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16681241     DOI: 10.1111/j.1754-4505.2006.tb01512.x

Source DB:  PubMed          Journal:  Spec Care Dentist        ISSN: 0275-1879


  4 in total

1.  Riga-Fede-like disease in a 70 year old woman.

Authors:  Uwe Wollina
Journal:  Indian J Dermatol       Date:  2010       Impact factor: 1.494

Review 2.  Mucous membrane pemphigoid.

Authors:  Hong-Hui Xu; Victoria P Werth; Ernesta Parisi; Thomas P Sollecito
Journal:  Dent Clin North Am       Date:  2013-08-15

3.  Treatment strategies in mucous membrane pemphigoid.

Authors:  Ann G Neff; Matthew Turner; Diya F Mutasim
Journal:  Ther Clin Risk Manag       Date:  2008-06       Impact factor: 2.423

4.  European Guidelines (S3) on diagnosis and management of mucous membrane pemphigoid, initiated by the European Academy of Dermatology and Venereology - Part II.

Authors:  E Schmidt; H Rashid; A V Marzano; A Lamberts; G Di Zenzo; G F H Diercks; S Alberti-Violetti; R J Barry; L Borradori; M Caproni; B Carey; M Carrozzo; G Cianchini; A Corrà; F G Dikkers; C Feliciani; G Geerling; G Genovese; M Hertl; P Joly; J M Meijer; V Mercadante; D F Murrell; M Ormond; H H Pas; A Patsatsi; S Rauz; B D van Rhijn; M Roth; J Setterfield; D Zillikens; G Zambruno; B Horváth; F Caux
Journal:  J Eur Acad Dermatol Venereol       Date:  2021-07-26       Impact factor: 6.166

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.